Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Medicines register
Registers› Irish medicines ›OxyNorm Dispersa 5 mg Orodispersible Tablets
Medicines register · Ireland

OxyNorm Dispersa 5 mg Orodispersible Tablets

Authorisation PA1688/006/007 · Mundipharma Pharmaceuticals Limited

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 21 Nov 2026
Licence holder
Mundipharma Pharmaceuticals Limited (all products →)
Active substance
OXYCODONE HYDROCHLORIDE
Clinical trials
7 clinical trials →
Dosage form
Orodispersible tablet
Route of administration
Oral use
ATC codes
N02AA, N02AA05
First authorised
16/07/2010
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

OXYCODONE HYDROCHLORIDE: supply and approvals

45 authorised products on the HPRA list contain OXYCODONE HYDROCHLORIDE. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 20 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 20 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 20 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 16 years (since 16 July 2010). The HPRA list marks it as marketed in Ireland.

Other medicines with OXYCODONE HYDROCHLORIDE in Ireland

44 other products on the HPRA list contain OXYCODONE HYDROCHLORIDE, from 7 licence holders; 23 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Dancex SR 10 mg Prolonged-Release TabletsRowex Limited,National authorisation (PA)Marketed
Dancex SR 20 mg Prolonged-Release TabletsRowex Limited,National authorisation (PA)Marketed
Dancex SR 5 mg Prolonged-Release TabletsRowex Limited,National authorisation (PA)Marketed
OxyContin 10 mg prolonged release tabletsMundipharma Pharmaceuticals LimitedNational authorisation (PA)Marketed
OxyContin 20 mg prolonged release tabletsMundipharma Pharmaceuticals LimitedNational authorisation (PA)Marketed
OxyContin 40 mg prolonged release tabletsMundipharma Pharmaceuticals LimitedNational authorisation (PA)Marketed
OxyContin 5 mg prolonged release tabletsMundipharma Pharmaceuticals LimitedNational authorisation (PA)Marketed
OxyNorm 10 mg hard capsulesMundipharma Pharmaceuticals LimitedNational authorisation (PA)Marketed
OxyNorm 10 mg/ml, solution for injection or infusionMundipharma Pharmaceuticals LimitedNational authorisation (PA)Marketed
OxyNorm 20 mg hard capsulesMundipharma Pharmaceuticals LimitedNational authorisation (PA)Marketed
OxyNorm 5 mg hard capsulesMundipharma Pharmaceuticals LimitedNational authorisation (PA)Marketed
OxyNorm 50 mg/ml, solution for injection or infusionMundipharma Pharmaceuticals LimitedNational authorisation (PA)Marketed

All 45 products with OXYCODONE HYDROCHLORIDE →

Other substances in ATC group N02AA

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 10 other active substances share the group N02AA with this product:

Morphine sulfate (10) · Naloxone hydrochloride dihydrate (7) · NALOXONE HYDROCHLORIDE (6) · Hydromorphone hydrochloride (5) · CYCLIZINE TARTRATE (2) · Morphine tartrate (1) · Morphine Tartrate BPC 1959 (1) · Dihydrocodeine tartrate (1) · Dihydrocodeine hydrorhodanide (1) · Dihydrocodeine Hydrogen Tartrate (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Mundipharma Pharmaceuticals Limited holds 47 products on the HPRA list, with 9 different active substances; 45 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.